Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pirko, I.
Right arrow Articles by Rodriguez, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirko, I.
Right arrow Articles by Rodriguez, M.
Related Collections
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow Multiple sclerosis

Neurology 2003;60:1697-1699
© 2003 American Academy of Neurology
Brief Communications

Contrasting effects of IFNß and IVIG in children with central and peripheral demyelination

I. Pirko, MD, N. L. Kuntz, MD, M. Patterson, MD, B. M. Keegan, MD, B. G. Weinshenker, MD and M. Rodriguez, MD

From the Departments of Neurology (Drs. Pirko, Kuntz, Keegan, Weinshenker, and Rodriguez) and Immunology (Dr. Rodriguez), Mayo Clinic, Rochester, MN; and Columbia University (Dr. Patterson), New York.

Address correspondence and reprint requests to Dr. M. Rodriguez, Department of Neurology, Mayo Clinic, 200 2 St. SW, Rochester, MN 55902; e-mail: rodriguez{at}mayo.edu

Reported are three children with MS who responded dramatically to interferon-ß (IFNß) therapy. While on immunomodulatory therapy, they developed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) that responded to IV immunoglobulin (IVIG) administration. These cases emphasize two interesting observations: 1) IFNß treatment did not prevent development of CIDP; 2) CIDP in the context of MS responded to IVIG, even though IVIG had no therapeutic effect on the central demyelinating disease.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
H Zephir, T Stojkovic, P Latour, A Lacour, J de Seze, O Outteryck, C-A Maurage, C Monpeurt, P Chatelet, E Ovelacq, et al.
Relapsing demyelinating disease affecting both the central and peripheral nervous systems
J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1032 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
G. Bernard, E. Riou, B. Rosenblatt, M.-E. Dilenge, and C. Poulin
Simultaneous Guillain-Barre Syndrome and Acute Disseminated Encephalomyelitis in the Pediatric Population
J Child Neurol, July 1, 2008; 23(7): 752 - 757.
[Abstract] [PDF]

Home page
 NeurologyHome page
B. C. Kieseier, H.-P. Hartung, D. Ekstein, and O. Abramsky
Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis
Neurology, March 28, 2006; 66(6): 955 - 955.
[Full Text] [PDF]

Home page
 NeurologyHome page
D. Ekstein, E. Linetsky, O. Abramsky, and D. Karussis
Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis
Neurology, August 9, 2005; 65(3): 456 - 458.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung
Chronic Inflammatory Demyelinating Polyneuropathy
N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.